Search Press releases Keywords From To 25 Apr 2024 UCB off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus Read More 23 Apr 2024 Transparency notification FMR LLC Read More 22 Apr 2024 UCB receives European Commission approval for BIMZELX[®]▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa Read More 19 Apr 2024 Acquisition of own shares Read More 17 Apr 2024 FINTEPLA[®]▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Read More 12 Apr 2024 Acquisition of own shares Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
